• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

Advertisement

Organisation › Details

Sequenom Center for Molecular Medicine (SCMM)

Sequenom Center for Molecular Medicine (Sequenom CMM(R)) is a CAP-accredited and CLIA-certified specialty reference laboratory dedicated to the development and commercialization of laboratory-developed genetic testing services for prenatal and eye conditions. Utilizing innovative proprietary technologies, Sequenom CMM provides genetic testing results services upon orders from physicians. Working closely with key opinion leaders and experts in obstetrics, retinal care and genetics, Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of laboratory tests. Sequenom CMM is changing the landscape in genetic diagnostics. *

 

	Start	2007-03-13 established_pre
	Group	Sequenom (Group)
	Industry	molecular diagnostics
	Industry 2	diagnostic services
	Region	Grand Rapids, MI
	Country	United States (USA)
	City	n. a. Grand Rapids, MI
		Address record changed: 2011-05-15
Basic data	Employees	n. a.
		* Document for »About Section«: Sequenom, Inc.. (12/22/10). "Press Release: Sequenom CMM Commences Pivotal Clinical Validation Study for Its SensiGene Trisomy 21 Laboratory Developed Test". San Diego, CA.
		Record changed: 2011-11-25

More documents for Sequenom (Group)

• [1] Atlas Biolabs GmbH. (7/23/10). "Press Release: Atlas Biolabs Expands Services in Molecular Genetics to High-throughput SNP-genotyping Based on Mass Spectrometry". Berlin....
• [2] Sequenom, Inc.. (5/12/10). "Press Release: Sequenom Announces $51.6 Million Private Placement". San Diego, CA....
• [3] Sequenom, Inc.. (4/19/10). "Press Release: Sequenom Introduces the MassARRAY Analyzer 4 System. Next-generation Proprietary Platform Makes High-performance Mass Spectrometry Available to Broad Market". San Diego, CA....
• [4] Sequenom, Inc.. (3/15/10). "Press Release: Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results. Full Year 2009 Revenues of $37.9 Million with Year End Cash and Equivalents of $42.7 Million". San Diego, CA....
• [5] Sequenom, Inc.. (2/16/10). "Press Release: Sequenom Announces Launch of SensiGene Fetal(XY) (Fetal Sex Determination)". San Diego, CA....
• [6] Sequenom, Inc.. (2/9/10). "Press Release: Sequenom Licenses Worldwide Rights to Develop Age-related Molecular Degeneration Diagnostic Test". San Diego, CA....
• [7] Sequenom, Inc.. (2/4/10). "Press Release: Sequenom Announces Launch of SensiGene Fetal RHD genotyping Test. First Commercial Test Using SEQureDx Technology for Determining Rhesus D Incompatibility". San Diego, CA....
• [8] Sequenom, Inc.. (9/28/09). "Press Release: Sequenom Announces Completion of Independent Investigation". San Diego, CA....
• [9] Sequenom, Inc.. (9/17/09). "Press Release: Sequenom Announces Launch of SensiGene Cystic Fibrosis Carrier Screening Test. First Commercial Test from Sequenom Center for Molecular Medicine". San Diego, CA....
• [10] Sequenom, Inc.. (9/9/09). "Press Release: Sequenom Announces Partnership with Geneworks for Sales and Marketing of MassARRAY Systems and Applications in Australia". San Diego, CA....

To subscribe to our free, monthly [MSC] Newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

NEW: Visit our brand new forthcoming web portals Life-Sciences-Germany.com and Life-Sciences-Europe.com

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2012. Made in Germany.